146 related articles for article (PubMed ID: 35902413)
1. Pediatric Heart Network Trial of Losartan vs. Atenolol in Children and Young Adults with Marfan Syndrome: Impact on Prescription Practices.
Robertson DM; Truong DT; Cox DA; Carmichael HL; Ou Z; Minich LL; Williams RV; Selamet Tierney ES
Pediatr Cardiol; 2023 Mar; 44(3):618-623. PubMed ID: 35902413
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.
Brooke BS; Habashi JP; Judge DP; Patel N; Loeys B; Dietz HC
N Engl J Med; 2008 Jun; 358(26):2787-95. PubMed ID: 18579813
[TBL] [Abstract][Full Text] [Related]
3. Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.
Chiu HH; Wu MH; Wang JK; Lu CW; Chiu SN; Chen CA; Lin MT; Hu FC
Mayo Clin Proc; 2013 Mar; 88(3):271-6. PubMed ID: 23321647
[TBL] [Abstract][Full Text] [Related]
4. The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis.
Kang YN; Chi SC; Wu MH; Chiu HH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):182-190. PubMed ID: 31003918
[TBL] [Abstract][Full Text] [Related]
5. Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome.
Teixido-Tura G; Forteza A; Rodríguez-Palomares J; González Mirelis J; Gutiérrez L; Sánchez V; Ibáñez B; García-Dorado D; Evangelista A
J Am Coll Cardiol; 2018 Oct; 72(14):1613-1618. PubMed ID: 30261963
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy.
Lacro RV; Guey LT; Dietz HC; Pearson GD; Yetman AT; Gelb BD; Loeys BL; Benson DW; Bradley TJ; De Backer J; Forbus GA; Klein GL; Lai WW; Levine JC; Lewin MB; Markham LW; Paridon SM; Pierpont ME; Radojewski E; Selamet Tierney ES; Sharkey AM; Wechsler SB; Mahony L;
Am Heart J; 2013 May; 165(5):828-835.e3. PubMed ID: 23622922
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.
Pitcher A; Spata E; Emberson J; Davies K; Halls H; Holland L; Wilson K; Reith C; Child AH; Clayton T; Dodd M; Flather M; Jin XY; Sandor G; Groenink M; Mulder B; De Backer J; Evangelista A; Forteza A; Teixido-Turà G; Boileau C; Jondeau G; Milleron O; Lacro RV; Sleeper LA; Chiu HH; Wu MH; Neubauer S; Watkins H; Dietz H; Baigent C;
Lancet; 2022 Sep; 400(10355):822-831. PubMed ID: 36049495
[TBL] [Abstract][Full Text] [Related]
8. Atenolol versus losartan in children and young adults with Marfan's syndrome.
Lacro RV; Dietz HC; Sleeper LA; Yetman AT; Bradley TJ; Colan SD; Pearson GD; Selamet Tierney ES; Levine JC; Atz AM; Benson DW; Braverman AC; Chen S; De Backer J; Gelb BD; Grossfeld PD; Klein GL; Lai WW; Liou A; Loeys BL; Markham LW; Olson AK; Paridon SM; Pemberton VL; Pierpont ME; Pyeritz RE; Radojewski E; Roman MJ; Sharkey AM; Stylianou MP; Wechsler SB; Young LT; Mahony L;
N Engl J Med; 2014 Nov; 371(22):2061-71. PubMed ID: 25405392
[TBL] [Abstract][Full Text] [Related]
9. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.
Lacro RV; Dietz HC; Wruck LM; Bradley TJ; Colan SD; Devereux RB; Klein GL; Li JS; Minich LL; Paridon SM; Pearson GD; Printz BF; Pyeritz RE; Radojewski E; Roman MJ; Saul JP; Stylianou MP; Mahony L;
Am Heart J; 2007 Oct; 154(4):624-31. PubMed ID: 17892982
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
Gambarin FI; Favalli V; Serio A; Regazzi M; Pasotti M; Klersy C; Dore R; Mannarino S; Viganò M; Odero A; Amato S; Tavazzi L; Arbustini E
J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):354-62. PubMed ID: 19430350
[TBL] [Abstract][Full Text] [Related]
11. Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome.
Van Driest SL; Sleeper LA; Gelb BD; Morris SA; Dietz HC; Forbus GA; Goldmuntz E; Hoskoppal A; James J; Lee TM; Levine JC; Li JS; Loeys BL; Markham LW; Meester JAN; Mital S; Mosley JD; Olson AK; Renard M; Shaffer CM; Sharkey A; Young L; Lacro RV; Roden DM
J Pediatr; 2020 Jul; 222():213-220.e5. PubMed ID: 32586526
[TBL] [Abstract][Full Text] [Related]
12. Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure.
Kim HJ; Jo SH; Lee MH; Seo WW; Choi JO; Ryu KH
Adv Ther; 2020 Sep; 37(9):3839-3849. PubMed ID: 32676928
[TBL] [Abstract][Full Text] [Related]
13. Comparison Between Beta-Blockers with Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers with Angiotensin II Type I Receptor Blockers in ST-Segment Elevation Myocardial Infarction After Successful Percutaneous Coronary Intervention with Drug-Eluting Stents.
Kim YH; Her AY; Jeong MH; Kim BK; Lee SY; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
Cardiovasc Drugs Ther; 2019 Feb; 33(1):55-67. PubMed ID: 30632033
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of the effect of angiotensin II receptor blocker versus β-blocker on aortic root growth in paediatric patients with Marfan syndrome.
Mueller GC; Stierle L; Stark V; Steiner K; von Kodolitsch Y; Weil J; Mir TS
Heart; 2014 Feb; 100(3):214-8. PubMed ID: 24270746
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic effect of angiotensin receptor blockers in children with genetic aortopathies: the early bird catches the worm.
Olfe J; Kanitz JJ; Stark VC; Stute F; von Kodolitsch Y; Biermann D; Huebler M; Kozlik-Feldmann R; Mir TS
Clin Res Cardiol; 2023 Nov; 112(11):1610-1619. PubMed ID: 37160466
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin Receptor Blockers vs. Beta-Blocker Therapy for Marfan Syndrome: A Systematic Review and Meta-Analysis.
Wang Z; Deng X; Kang X; Hu A
Ann Vasc Surg; 2022 May; 82():347-361. PubMed ID: 34998935
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis Examining the Usefulness of Angiotensin Receptor blockers for the Prevention of Aortic Root Dilation in Patients With the Marfan Syndrome.
Al-Abcha A; Saleh Y; Mujer M; Boumegouas M; Herzallah K; Charles L; Elkhatib L; Abdelkarim O; Kehdi M; Abela GS
Am J Cardiol; 2020 Aug; 128():101-106. PubMed ID: 32650901
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of the pharmacological management of aortic root dilation in Marfan syndrome.
Thakur V; Rankin KN; Hartling L; Mackie AS
Cardiol Young; 2013 Aug; 23(4):568-81. PubMed ID: 23083542
[TBL] [Abstract][Full Text] [Related]
19. Recent Clinical Drug Trials Evidence in Marfan Syndrome and Clinical Implications.
Singh MN; Lacro RV
Can J Cardiol; 2016 Jan; 32(1):66-77. PubMed ID: 26724512
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double blind pilot study to assess the effects of losartan vs. atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes.
Sandor GG; Alghamdi MH; Raffin LA; Potts MT; Williams LD; Potts JE; Kiess M; van Breemen C
Int J Cardiol; 2015 Jan; 179():470-5. PubMed ID: 25465809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
